These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 28467432)

  • 21. Immunoglobulin A and CD8 T-cell mucosal immune defenses protect against intranasal infection with Chlamydia pneumoniae.
    Rodríguez A; Rottenberg M; Tjärnlund A; Fernández C
    Scand J Immunol; 2006 Mar; 63(3):177-83. PubMed ID: 16499570
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Intranasal priming with HIV DNA vaccine and systemic boosting with recombinant vaccinia induce vigorous immune responses: experiment with mice].
    Huang XG; Xu JQ; Ren L; Qiu C; Zhang N; Liu LX; Wan YM; Peng H; Shao YM
    Zhonghua Yi Xue Za Zhi; 2006 Nov; 86(44):3109-13. PubMed ID: 17313761
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immune response characterization of mice immunized with Lactobacillus plantarum expressing spike antigen of transmissible gastroenteritis virus.
    Yang WT; Li QY; Ata EB; Jiang YL; Huang HB; Shi CW; Wang JZ; Wang G; Kang YH; Liu J; Yang GL; Wang CF
    Appl Microbiol Biotechnol; 2018 Oct; 102(19):8307-8318. PubMed ID: 30056514
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of fowlpox-vaccinia virus prime-boost vaccine strategies for high-level mucosal and systemic immunity against HIV-1.
    Ranasinghe C; Medveczky JC; Woltring D; Gao K; Thomson S; Coupar BE; Boyle DB; Ramsay AJ; Ramshaw IA
    Vaccine; 2006 Jul; 24(31-32):5881-95. PubMed ID: 16759767
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heterotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of Chlamydia trachomatis by prior immunization with recombinant serovar L1 major outer-membrane protein.
    Tuffrey M; Alexander F; Conlan W; Woods C; Ward M
    J Gen Microbiol; 1992 Aug; 138 Pt 8():1707-15. PubMed ID: 1527511
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of immune responses and protective efficacy of intranasal prime-boost immunization regimens using adenovirus-based and CpG/HH2 adjuvanted-subunit vaccines against genital Chlamydia muridarum infection.
    Brown TH; David J; Acosta-Ramirez E; Moore JM; Lee S; Zhong G; Hancock RE; Xing Z; Halperin SA; Wang J
    Vaccine; 2012 Jan; 30(2):350-60. PubMed ID: 22075089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Humoral immune responses by prime-boost heterologous route immunizations with CTB-MPR(649-684), a mucosal subunit HIV/AIDS vaccine candidate.
    Matoba N; Geyer BC; Kilbourne J; Alfsen A; Bomsel M; Mor TS
    Vaccine; 2006 Jun; 24(23):5047-55. PubMed ID: 16621185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Induction of mucosal immunity by inactivated poliovirus vaccine is dependent on previous mucosal contact with live virus.
    Herremans TM; Reimerink JH; Buisman AM; Kimman TG; Koopmans MP
    J Immunol; 1999 Apr; 162(8):5011-8. PubMed ID: 10202050
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Per-oral immunization with antigen-conjugated nanoparticles followed by sub-cutaneous boosting immunization induces long-lasting mucosal and systemic antibody responses in mice.
    Howe SE; Konjufca VH
    PLoS One; 2015; 10(2):e0118067. PubMed ID: 25710518
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines.
    Patel GB; Zhou H; Ponce A; Chen W
    Vaccine; 2007 Dec; 25(51):8622-36. PubMed ID: 17959279
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity and protection against genital Chlamydia infection and its complications by a multisubunit candidate vaccine.
    Ifere GO; He Q; Igietseme JU; Ananaba GA; Lyn D; Lubitz W; Kellar KL; Black CM; Eko FO
    J Microbiol Immunol Infect; 2007 Jun; 40(3):188-200. PubMed ID: 17639158
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunogenicity of recombinant
    Liu YY; Yang WT; Shi SH; Li YJ; Zhao L; Shi CW; Zhou FY; Jiang YL; Hu JT; Gu W; Yang GL; Wang CF
    J Vet Sci; 2017 Jun; 18(2):159-167. PubMed ID: 27456769
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Intranasal vaccination of recombinant H5N1 HA1 proteins fused with foldon and Fc induces strong mucosal immune responses with neutralizing activity: Implication for developing novel mucosal influenza vaccines.
    Yu F; Li Y; Guo Y; Wang L; Yang J; Zhao G; Zhou Y; Du L; Jiang S
    Hum Vaccin Immunother; 2015; 11(12):2831-8. PubMed ID: 26260706
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protective immunity against Chlamydia trachomatis can engage both CD4+ and CD8+ T cells and bridge the respiratory and genital mucosae.
    Nogueira CV; Zhang X; Giovannone N; Sennott EL; Starnbach MN
    J Immunol; 2015 Mar; 194(5):2319-29. PubMed ID: 25637024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The mucosal immune response to Chlamydia trachomatis infection of the reproductive tract in women.
    Agrawal T; Vats V; Salhan S; Mittal A
    J Reprod Immunol; 2009 Dec; 83(1-2):173-8. PubMed ID: 19896206
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lactobacillus plantarum displaying CCL3 chemokine in fusion with HIV-1 Gag derived antigen causes increased recruitment of T cells.
    Kuczkowska K; Mathiesen G; Eijsink VG; Øynebråten I
    Microb Cell Fact; 2015 Oct; 14():169. PubMed ID: 26494531
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mucosal immunization using proteoliposome and cochleate structures from Neisseria meningitidis serogroup B induce mucosal and systemic responses.
    Campo JD; Zayas C; Romeu B; Acevedo R; González E; Bracho G; Cuello M; Cabrera O; Balboa J; Lastre M
    Methods; 2009 Dec; 49(4):301-8. PubMed ID: 19410000
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chlamydia trachomatis and male infertility: chlamydia-IgA antibodies in seminal plasma are C. trachomatis specific and associated with an inflammatory response.
    Ochsendorf FR; Ozdemir K; Rabenau H; Fenner T; Oremek R; Milbradt R; Doerr HW
    J Eur Acad Dermatol Venereol; 1999 Mar; 12(2):143-52. PubMed ID: 10343944
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bacterium-like particles supplemented with inactivated influenza antigen induce cross-protective influenza-specific antibody responses through intranasal administration.
    de Haan A; Haijema BJ; Voorn P; Meijerhof T; van Roosmalen ML; Leenhouts K
    Vaccine; 2012 Jul; 30(32):4884-91. PubMed ID: 22537989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Induction of mucosal and systemic immunity against respiratory syncytial virus by inactivated virus supplemented with TLR9 and NOD2 ligands.
    Shafique M; Wilschut J; de Haan A
    Vaccine; 2012 Jan; 30(3):597-606. PubMed ID: 22120195
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.